GlassScriptPhysician profile
Sarah Kasprowicz
NPI 1760659981
$3,478.55
in general payments reported to CMS, 2019-2025
20 companies · $771 in 2025
The $771 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $106 · 2021: $23.98 · 2022: $204 · 2023: $894 · 2024: $1,038 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.04 |
| Education | $228.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.71 | 2019-2025 | |
| Janssen Biotech, INC. | $587.30 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $458.29 | 2023-2025 | Dupixent |
| Amgen INC. | $289.72 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $280.83 | 2019-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $148.87 | 2023-2025 | |
| Dermira, INC. | $117.99 | 2019 | |
| Leo Pharma INC. | $86.05 | 2022-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $79.55 | 2023-2025 | Zoryve |
| Pfizer INC. | $75.85 | 2024 | |
| Dermavant Sciences, INC. | $70.95 | 2023 | Vtama |
| Genzyme Corporation | $67.56 | 2019-2024 | |
| Lilly USA, LLC | $56.07 | 2023-2024 | Taltz |
| Botanix Sb INC | $46.15 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $38.78 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $24.90 | 2023 | Ilumya |
| Ucb, INC. | $18.76 | 2023 | Bimzelx |
| Strata Skin Sciences, INC. | $15.19 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $14.40 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $13.63 | 2025 | Clindacin Etz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Kasprowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.